secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2023-08-17T23:59:59+00:00
Accession:  0001193125-23-214706
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Selecta posts Q2 net loss of $11.4M; suspends pipeline investment to focus on SEL-212 BLA filing in 1H 2024
--------------------------------------------------------------------------------

- Net loss of $11.4M ($0.07/share) vs net income of $8.6M ($0.06) in Q2 2022; collaboration revenue fell to $5.2M from $39.3M.
- Cash, equivalents, restricted cash, marketable securities $115.0M as of June 30, 2023; expected to fund operations into 2027.
- BLA submission for SEL-212 (chronic refractory gout) on track for 1H 2024; eligible for up to $615M in remaining milestone payments from Sobi.
- Halting further investment in pipeline assets including ImmTOR-IL; evaluating licensing/corporate development for pipeline programs.
- Partnership with Astellas for Xork IgG protease in LOPD continues; Xork designed to expand gene therapy access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000119312523214706/0001193125-23-214706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000119312523214706/d541263d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-214706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer